Core Viewpoint - A class-action lawsuit has been filed against James Hardie Industries plc, alleging securities fraud related to misleading investors about inventory levels and customer demand in its North American segment [1][12]. Summary by Sections Lawsuit Details - The lawsuit, titled Laborers' District Council & Contractors' Pension Fund of Ohio v. James Hardie Industries PLC., was filed on behalf of investors who purchased James Hardie common stock between May 20, 2025, and August 18, 2025 [3]. - The lawsuit seeks damages for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [3]. Allegations of Misleading Information - The action focuses on James Hardie's North America Fiber Cement segment, which accounts for approximately 80% of the company's total earnings [4]. - Plaintiffs allege that management denied significant inventory destocking trends observed in April and May 2025, misleading investors about the segment's strength [4][5]. Impact of Allegations - The complaint highlights that company executives made statements around May 20 and 21, 2025, falsely claiming robust customer demand and denying inventory destocking [5]. - The lawsuit claims that sales were artificially inflated due to "inventory loading by channel partners," indicating potential fraudulent practices [5]. Performance Disclosure - On August 19, 2025, James Hardie disclosed a 12% decline in sales in the North America Fiber Cement division, attributing it to the customer destocking previously denied [6]. - The CEO characterized the downturn as a "normalization of channel inventories," but warned of continued impacts on sales for at least the next two quarters [6]. Market Reaction - Following the disclosure of the decline, James Hardie's stock price fell by over 34%, leading to significant losses for investors [7]. - The lawsuit aims to recover damages for investors who suffered financial injuries due to the alleged wrongful acts during the class period [7]. Investigation by Hagens Berman - Hagens Berman is investigating the claims and is seeking information from investors who may have suffered losses or have knowledge relevant to the investigation [8].

Core Viewpoint - Stride, Inc. is under investigation for potential violations of federal securities laws, following a significant drop in its stock price due to poor customer experiences stemming from platform changes [1][4]. Company Overview - Stride, Inc. is an education technology company that offers an online platform for students across the U.S. [2]. Recent Developments - Stride reported "record demand" for its products and services during the relevant period, claiming that customers were choosing its offerings in increasing numbers [2]. - However, the company faced backlash due to unpopular platform changes that negatively impacted customer experiences, leading to a loss of students [3]. Financial Impact - On October 28, 2025, Stride disclosed that its growth rate did not meet expectations due to poorly executed upgrades, which resulted in a "poor customer experience" [4]. - The company estimated a loss of approximately 10,000-15,000 enrollments, leading to a "muted" outlook compared to previous years [4]. - Following this announcement, Stride's stock price plummeted over 50% during trading on October 29, 2025 [4].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Varonis Systems, Inc. for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Investigation Details - The investigation is focused on Varonis Systems, Inc. following the release of its third quarter 2025 financial results on October 28, 2025 [1]

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into Nidec Corporation regarding potential violations of federal securities laws, specifically targeting investors who may have incurred losses [1] Company Investigation - The investigation is focused on Nidec Corporation (OTC: NJDCY) and aims to assess the company's compliance with federal securities regulations [1] - Investors who have lost money on Nidec Corporation are encouraged to inquire about pursuing claims to recover their losses [1]

Core Viewpoint - A class action securities fraud lawsuit has been filed against KinderCare Learning Companies, Inc. to recover losses for investors affected by alleged fraudulent activities related to the company's initial public offering in October 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit alleges that KinderCare made false statements and concealed incidents of child abuse, neglect, and harm at its facilities [3]. - It is claimed that KinderCare failed to provide the "highest quality care possible" and did not meet minimum standards in the child care industry, exposing the company to undisclosed risks of lawsuits and reputational damage [3]. Group 2: Investor Information - Investors who suffered losses in KinderCare stock during the relevant timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. - The lawsuit is on behalf of all purchasers of KinderCare common stock in or traceable to the company's October 2024 initial public offering [2]. Group 3: Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, is representing the plaintiffs and has a strong track record in securing recoveries for shareholders [5].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Netflix, Inc. and may file a class action on behalf of investors [1][3]. Group 1: Investigation Details - The investigation focuses on whether Netflix's board and officers failed to provide adequate oversight and disclosure regarding a significant tax dispute in Brazil [3]. - Following the release of its third-quarter earnings, Netflix's stock fell approximately 10% on October 22, 2025, due to a one-time $619 million tax charge related to the Brazilian legal dispute [3]. Group 2: Allegations and Concerns - Investors allege that Netflix's handling of the tax matter, including the timing and characterization of the expense, related disclosures, and the adequacy of board-level controls, raises questions about potential breaches of fiduciary duty and internal controls [3]. - The decline in stock price was attributed to the impact of the tax charge on the company's profit margins, despite otherwise strong growth [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Semler Scientific, Inc. securities about the lead plaintiff deadline for a securities class action lawsuit, emphasizing the potential for compensation without upfront costs for eligible investors [1][2]. Group 1: Class Action Details - The class action pertains to securities purchased between March 10, 2021, and April 15, 2025, with a lead plaintiff deadline set for October 28, 2025 [1]. - Investors who wish to join the class action can do so through a provided link or by contacting the firm directly [3][6]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [3]. Group 2: Legal Background - The lawsuit alleges that Semler Scientific made materially false and misleading statements and failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act [5]. - The claims suggest that the defendants' public statements were misleading, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for securities fraud, related to safety issues with its Novum IQ Large Volume Pump, which has led to significant stock price decline and investor losses [1][5][6]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz are encouraging Baxter shareholders to inquire about a class action lawsuit filed on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1][2]. Safety Issues - On April 7, 2025, a Missouri news outlet reported serious safety concerns regarding Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Following this, Baxter issued warning letters about potential underinfusion risks, later revealing 79 reports of serious injuries and two patient deaths associated with the device [4]. Stock Price Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, resulting in a stock price drop of $6.24, or 22.4%, closing at $21.61 per share [5]. Allegations in the Lawsuit - The lawsuit alleges that Baxter made materially false and misleading statements and failed to disclose critical information about the Novum LVP's systemic defects, which posed risks of serious injury or death to patients [6][7]. - Specific allegations include the company's knowledge of device malfunctions, inadequate remedial measures, and misleading positive statements about its business prospects [7].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) for securities fraud, following disappointing Phase 3 results for its drug candidate sonelokimab (SLK) [1][3]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz announced a class action lawsuit on behalf of shareholders who purchased MLTX common stock between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. Disappointing Drug Results - On September 28, 2025, MoonLake announced that SLK failed to match the efficacy of its competitor's drug, BIMZELX, despite prior claims of its superiority [3]. - The company had promoted SLK's nanobody structure as superior but allegedly did not disclose that it targeted the same molecules as BIMZELX and lacked proven advantages [3]. Stock Price Impact - Following the announcement of the disappointing results, MoonLake's stock plummeted by $55.74, or 89.9%, closing at $6.24 per share on September 29, 2025, significantly harming investors [4]. Allegations in the Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, including: 1. SLK and BIMZELX share the same molecular targets [5]. 2. SLK's nanobody structure would not provide superior clinical benefits over BIMZELX [5]. 3. The supposed increased tissue penetration of SLK would not translate to clinical efficacy [5]. 4. Positive statements about the company's business were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - The James Hardie Industries plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors about its sales performance during a period of inventory destocking [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc" and covers purchasers of James Hardie common stock from May 20, 2025, to August 18, 2025 [1]. - Investors have until December 23, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that James Hardie executives made false statements about the strength of the North America Fiber Cement segment, despite evidence of inventory destocking [3]. Group 2: Financial Impact - On August 19, 2025, James Hardie disclosed a 12% decline in sales in the North America Fiber Cement segment, attributed to customer destocking [4]. - Following this disclosure, the company's stock price dropped by over 34% [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased James Hardie common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].